Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis
Brief Summary: Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.


Options:
A: Arm Label: FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: GSK2190915 200mg QD (AM), Drug: GSK2190915 100mg QD (AM), Drug: Placebo capsule (PM) | Arm Label: FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM); Type: ACTIVE_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Montelukast 10mg QD (PM), Drug: Placebo tablets (2) (AM) | Arm Label: FP/SAL 250/50mcg BID plus placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Placebo tablets (2) (AM), Drug: Placebo capsule (PM) | Intervention Type: DRUG; Name: FP/SAL 250/50mcg BID; Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: GSK2190915 200mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: GSK2190915 100mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: Montelukast 10mg QD (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM) | Intervention Type: DRUG; Name: Placebo tablets (2) (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: Placebo capsule (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus placebo BID
B: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
C: Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Singular pill; Type: EXPERIMENTAL; Interventions: Drug: singular | Intervention Type: DRUG; Name: singular; Assigned to Arm(s): Singular pill | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo pill
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1

Answer: D